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Cardiovascular Safety During Treatment With Baricitinib in 
Rheumatoid Arthritis
Peter C. Taylor,1 Michael E. Weinblatt,2 Gerd R. Burmester,3 Terence P. Rooney,4 Sarah Witt,4 Chad D. Walls,4 
Maher Issa,4 Claudia A. Salinas,4 Chadi Saifan,4 Xin Zhang,4 Anabela Cardoso,4 Miguel A. González-Gay,5 and 
Tsutomu Takeuchi6
Objective. To assess the frequency of cardiovascular and venous thromboembolic events in clinical studies 
of baricitinib, an oral, selective JAK1 and JAK2 inhibitor approved in more than 50 countries for the treatment of 
moderately- to- severely active rheumatoid arthritis (RA).
Methods. Data were pooled from 9 RA studies. Placebo comparison up to 24 weeks included data from 6 studies. 
Randomized dose comparison between baricitinib doses of 2 mg and 4 mg used data from 4 studies and from the as-
sociated long-term extension study. The data analysis set designated “All- bari- RA” included all baricitinib exposures 
at any dose.
Results. Overall, 3,492 RA patients received baricitinib (7,860 patient- years of exposure). No imbalance compared 
to the placebo group was seen in the incidence of major adverse cardiovascular events (MACE) (incidence rates [IRs] 
of 0.5 per 100 patient-years for placebo and 0.8 per 100 patient-years for 4 mg baricitinib), arterial thrombotic events 
(ATE) (IRs of 0.5 per 100 patient-years for placebo and 0.5 per 100 patient-years for 4 mg baricitinib), or congestive heart 
failure (CHF) broad term (IRs of 4.3 per 100 patient-years for placebo and 2.4 per 100 patient-years for 4 mg baricitinib). 
Deep vein thrombosis (DVT)/pulmonary embolism (PE) were reported in 0 of 1,070 patients treated with placebo and 6 
of 997 patients treated with 4 mg  baricitinib during the placebo- controlled period; these events were serious in 2 of 6 pa-
tients, while all 6 had risk factors and 1 patient developed DVT/PE after discontinuation of the study drug. In the 2 mg– 
4 mg-extended data analysis set, IRs of DVT/PE were comparable between the doses across event types (IRs of 0.5 per 
100 patient- years in those receiving 2 mg baricitinib and 0.6 per 100 patient- years in those receiving 4 mg baricitinib). 
In the All- bari- RA data analysis set, the rates were stable over time, with an IR of DVT/PE of 0.5 per 100 patient- years.
Conclusion. In RA clinical trials, no association was found between baricitinib treatment and the incidence of 
MACE, ATE, or CHF. With regard to incidence of DVT/PE, 6 events occurred in patients treated with 4 mg baricitinib, 
but no cases of DVT/PE were reported in the placebo group. During longer- term evaluation, the incidence of DVT/PE 
was similar between the baricitinib dose groups, with consistent IR values over time, and this was similar to the rates 
previously reported in patients with RA.
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INTRODUCTION
The goals of rheumatoid arthritis (RA) treatment are to mini-
mize synovial inflammation, prevent joint destruction, and improve 
quality of life. Strategies used to achieve these goals include early 
diagnosis and treatment with disease- modifying antirheumatic 
drugs (DMARDs), the doses of which are adjusted according to 
the levels of disease activity to achieve targets such as remis-
sion or low disease activity. Over the last few decades, efficacious 
DMARDs have been developed and are used in clinical practice. 
Efficacy and tolerability of conventional synthetic DMARDs, such 
as the anchor drug methotrexate (MTX), and a number of biologic 
DMARDs targeting individual cytokines, their receptors, specific 
cells, or costimulatory molecules have been well recognized. Nev-
ertheless, insufficient response rates, loss of response, exclusion 
of patients with comorbidities, which could confound treatment 
decisions and adherence, and several safety signals, such as 
infections, have been reported to date in patients treated with 
these agents.
JAK inhibitors, which target cytokine signaling pathways 
implicated in RA pathogenesis, provide alternative treatment 
options in RA. Baricitinib, an oral, selective JAK1 and JAK2 inhib-
itor, has shown clinical efficacy and acceptable safety in clinical 
trials involving patients with RA (1–5). Baricitinib is approved for 
the treatment of adults with moderately- to- severely active RA in 
more than 50 countries, including many European countries as 
well as Japan and the United States.
Cardiovascular (CV) diseases may lead to life- threatening 
sequelae, affecting mortality and morbidity. Thromboembolism 
can affect arterial or venous vessels, and may lead to ischemia 
or congestion with subsequent tissue damage. Compared to 
the general population, patients with RA have a 69% (95% con-
fidence interval [95% CI] 50–90%) greater risk of CV diseases 
of arterial ischemic origin, such as myocardial infarction (MI) 
and stroke, according to data from a recent meta- analysis of 
12 studies, and a 60–140% increased risk of venous thrombo-
embolism (VTE) (6–9). Increased incidence of subclinical athero-
sclerosis, manifested by an abnormally high frequency of carotid 
plaques, is observed in patients with RA (10), suggesting that 
systemic inflammation in RA may contribute to increased arte-
rial CV risk in addition to the conventional risk factors (11–13). 
Moreover, a genetic component also appears to be involved in 
the increased risk of endothelial dysfunction and atherosclerotic 
disease observed in patients with RA (14).
The frequency of thromboembolic events in the RA popu-
lation has been studied over the last decade, with incidence 
rates (IRs) reported to be 2–3 times higher than in the healthy 
population (15–17). Herein, we analyzed the CV safety profile of 
 baricitinib in patients with RA, based on integrated data from 9 
clinical trials (during both placebo- controlled and non–placebo- 
controlled periods), including phase II, phase III, and an ongoing 
long-term extension (LTE) study.
PATIENTS AND METHODS
Study design and patients. The data reported herein 
were from 9 RA clinical trials (1 completed phase I, 3 completed 
phase II, 4 completed phase III, and data through April 1, 2017 
from 1 ongoing phase III LTE study) (1–4,18–21) (Table 1). Baric-
itinib doses ranged from 1 mg to 15 mg once daily, with doses 
of 2 mg and 4 mg in the phase III studies. Across the phase III 
studies (including the LTE study), patients with an inadequate 
response could receive rescue therapy with 4 mg baricitinib 
after specified time points. Patients completing phase III stud-
ies were eligible to enter the ongoing LTE study (RA- BEYOND), 
which provides up to 336 weeks of exposure to baricitinib (21). 
Patients who were randomized to receive 2 mg baricitinib and 
who had not received rescue therapy in the originating study 
continued to receive 2 mg baricitinib in the LTE study; all other 
patients received 4 mg baricitinib. Patients receiving 4 mg baric-
itinib for at least 15 months without rescue therapy and who 
achieved sustained low disease activity (a Clinical Disease Activ-
ity Index [CDAI] score ≤10) or remission (a CDAI score ≤2.8) (22) 
were re- randomized in a blinded manner to continue on 4 mg 
baricitinib or to taper the dose to 2 mg. Patients in the phase II 
study NCT01185353 were also eligible for the LTE and were 
treated with 4 mg baricitinib.
All studies were conducted in accordance with the ethics 
principles of the Declaration of Helsinki and Good Clinical Prac-
tice Guidelines, and were approved by each center’s institutional 
review board or ethics committee. All patients provided written 
informed consent.
Data analysis sets. Patient- level data were analyzed for the 
following data analysis sets. 1) The placebo- controlled data set 
included data from placebo- treated and 4 mg baricitinib–treated 
patients from 6 trials (phases II and III), in which patients could be 
randomized to receive either placebo or 4 mg baricitinib through 
24 weeks of treatment or to the end of the placebo- controlled 
period, with data censored at rescue. Data were also included 
for patients who received 2 mg baricitinib from 4 of these trials, in 
which patients could be randomized to receive either placebo, 2 
mg baricitinib, or 4 mg baricitinib through 24 weeks of treatment 
or to the end of the placebo- controlled period, with data censored 
at rescue.
2) The 2 mg–4 mg-extended data set included data from 4 
studies (phases II and III) in which patients could be randomized 
to receive either placebo, 2 mg baricitinib, or 4 mg baricitinib, and 
also included data from the extended LTE study, with data cen-
sored at rescue or dose change.
3) The All- bari- RA data set included data from patients who 
received at least 1 dose (any dose level) of baricitinib from all 9 
of the RA studies, and included all data available after the start 
of the first baricitinib dose, without censoring for rescue or dose 
change.
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Data analysis sets 1 and 2 allowed comparisons between 
treatment groups using all available data, while preserving ran-
domization. Set 1 allowed a randomized comparison between 
4 mg baricitinib and placebo (with the data for 2 mg baricitinib 
presented from a subset of studies for reference), and set 2 pro-
vided a randomized comparison between the doses. Set 3 was 
Table 1. Baricitinib clinical trial information and associated data analysis sets*






Study I4V- MC- 
JADB (open- 
label) (18)
Bari 15 mg; Bari 10 
mg; Bari 5 mg 
BID





Placebo; Bari 8 mg; 
Bari 4 mg; Bari 2 






MTX- IR; bDMARD 
naive
– 12 weeks DB; 12 
weeks BE; 52 




Placebo; Bari 10 





csDMARD- IR; prior 
bDMARD 
allowed





Placebo; Bari 8 mg; 
Bari 4 mg; Bari 2 






MTX- IR; prior 
bDMARD 
allowed§











MTX- IR; bDMARD 
naive
16 24 weeks DB; 28 





























MTX mono; Bari 4 
mg mono; Bari 4 
mg + MTX






Bari 4 mg; Bari 2 
mg
2 mg–4 mg- 
extended; 
All- bari- RA
Varied PRN Up to 6.1 years††
* RA = rheumatoid arthritis; bari = baricitinib; BID = twice- daily; MTX = methotrexate; IR = inadequate response; BE = blinded extension with 
no placebo; OE = open- label extension; csDMARD = conventional synthetic disease- modifying antirheumatic drug; TNFi = tumor necrosis 
factor inhibitor; mono = monotherapy; PRN = as needed. 
† First available rescue. 
‡ Data from phase II/III studies contributed to the population pharmacokinetics analysis. 
§ Prior biologic disease- modifying antirheumatic drugs (bDMARDs) were allowable; however, patients could not have stopped treatment due 
to insufficient response. 
¶ Double- blind (DB) with no placebo. 
# The trial RA- BEAM had 24 weeks of placebo control and 52 weeks of active control. 
** Trials contributing to the long- term extension (LTE) RA- BEYOND study included the phase II trial NCT01185353 and phase III trials RA- 
BEAM, RA- BEACON, RA- BUILD, and RA- BEGIN. 
†† Ongoing trial with data as of April 1, 2017. 
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uncontrolled and combined baricitinib dose groups to maximize 
the patient- years of exposure, and therefore was most pre-
cise in estimating the IRs. Two of the individual phase III stud-
ies included active comparators: MTX from the RA- BEGIN trial, 
and  adalimumab from the RA- BEAM trial (1,2). Data by treatment 
group from these studies are shown for selected major topic cat-
egories.
Evaluation of events. In phase III trials, potential major 
adverse cardiovascular events (MACE) (including MI, stroke, 
and CV death) and other CV events (hospitalization for unstable 
angina, hospitalization for heart failure, serious arrhythmia, resus-
citated sudden death, cardiogenic shock, or coronary revascu-
larizations) were adjudicated by an independent, external Clinical 
Endpoint Committee. Arterial thrombotic events (ATE) comprising 
MI and ischemic stroke, along with Medical Dictionary for Regula-
tory Activities (MedDRA) preferred terms indicative of other acute 
ATE, were recorded; where available (phase III for applicable event 
types), adjudicated data were used.
Deep vein thrombosis (DVT) and pulmonary embolism (PE) 
were not independently adjudicated. Review was conducted by 
the study sponsor’s medical staff to identify reported events of 
DVT and PE, using a standardized MedDRA query (SMQ) from 
the Embolic and Thrombotic Events SMQ, including all sub- SMQs 
in addition to MedDRA preferred terms of “deep vein thrombosis” 
and “pulmonary embolism.”
Serious adverse events (SAEs) were recorded as any event 
that, in the opinion of the investigator, met the International Con-
ference on Harmonisation seriousness criteria (23). For conges-
tive heart failure (CHF), signal detection analysis was conducted 
using the broad and narrow terms of the Cardiac Failure SMQ.
Statistical analysis. Comparisons between placebo and 
each baricitinib dose group were performed using the Cochran- 
Mantel- Haenszel test, stratified by study. Exposure- adjusted IRs 
were calculated as the number of unique patients with an event 
per 100 patient- years of exposure time. For AEs of special inter-
est, IRs were calculated as the number of unique patients with an 
event per 100 patient- years of observation time, which included 
any posttreatment follow- up time, censored at the event.
A Cox regression model was used to investigate the effect 
of potential risk factors on the occurrence of DVT/PE and its 
timing relative to receipt of the first dose of baricitinib, using the 
all- bari- RA data analysis set. Factors were screened using a 
single- factor model at the nominal statistical significance level of 
0.05 (2- sided). The set of significant factors was included in a 
multivariable, stepwise (forward and backward) selection regres-
sion model, using a P value of 0.20 as the model entry criterion 
and a P value of 0.10 as the requirement to remain in the model, 
stopping when no additional factors could be added or removed 
from the model.
Plasma baricitinib concentration. To explore any 
potential relationship between AEs and baricitinib exposure, 
plasma baricitinib concentrations were compared between 
patients who developed DVT/PE and those without such events. 
The steady- state peak concentration and total daily exposure 
at steady state of dosing in individual patients were estimated 
based on a previously described phase II/phase III population 
pharmacokinetics analysis that included 7 of the phase II and 
phase III studies (24) (see Table 1).
RESULTS
Patients and exposure. The characteristics of the RA 
patients within each data analysis set were generally similar 
across treatment groups, although in the placebo- controlled 
data set, more patients were age ≥65 years in the 4 mg 
 baricitinib group than in the placebo group (20% versus 16%) 
(Table 2). In the All- bari- RA data set, the mean age at baseline 
was 53 years, 79% were female, and time since RA diagnosis 
was 8 years. Approximately 50% of patients were taking cor-
ticosteroids at the time of the first baricitinib dose, and 76% 
were receiving concomitant MTX. The baseline disease activ-
ity included a mean swollen joint count of 12 (based on 66 
joints assessed), mean tender joint count of 20 (based on 68 
joints assessed), mean CDAI score of 31, and mean Disease 
Activity Score in 28 joints (25) using C- reactive protein level of 
5.1. Patients had varied prior experience with RA treatments, 
ranging from being naive to treatment with DMARDs to hav-
ing received more than 3 biologic DMARDs, which is reflective 
of the patient populations enrolled by design in the different 
phase III studies.
In the All- bari- RA data analysis set, 3,492 patients 
received at least 1 dose of baricitinib, for a total of 7,860.3 
patient- years of exposure; 78% of patients had ≥1 year of 
treatment and 63% had ≥2 years of treatment, with a maximum 
exposure of 6.1 years (Table  2). Most patients (81%) in the 
All- bari- RA data set were exposed to the 4 mg dose of baric-
itinib. In the placebo- controlled data set, 1,070 patients who 
received placebo and 997 patients who received 4 mg baric-
itinib were treated for 393.8 patient- years and 409.4 patient- 
years, respectively. In the 2 mg–4 mg-extended data set, 479 
patients received 2 mg baricitinib and 479 patients received 
4 mg baricitinib; those who were treated with 4 mg baricitinib 
had a greater number of patient- years of exposure compared 
to the 2 mg dose group (645.9 patient- years of exposure ver-
sus 604.9 patient- years of exposure). Furthermore, more 4 
mg baricitinib–treated patients had ≥1 year of exposure (48% 
versus 36% of the 2 mg  baricitinib–treated patients), while the 
percentages of patients with ≥2 years of exposure were similar 
between the baricitinib dose groups (22% of the 4 mg–treated 
patients versus 26% of the 2 mg–treated patients).
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Incidence rates of MACE, ATE, and CHF. During the 
24- week placebo- controlled period, IRs of adjudicated MACE 
were comparable between the placebo group and the 4 mg 
baricitinib group (IRs of 0.5 per 100 patient- years [95% CI 0.1–2.0] 
and 0.8 per 100 patient- years [95% CI 0.2–2.2], respectively), with 
no clear dose response during extended observation (Figure 1A). 
The IRs for the individual MACE components (MI, stroke, and CV- 
related death) were also similar between the groups (Table 3). The 
IR of MACE in the All- bari- RA data set was 0.5 per 100 patient- 
years, and remained stable over time (Figure 1B). No association 
between increased low- density lipoprotein (LDL) cholesterol levels 
and incidence of MACE was identified (26) (see Supplementary 
Figure 1, available on the Arthritis & Rheumatology web site at 
http:// onlinelibrary.wiley.com/doi/10.1002/art.40841/abstract).
IRs of ATE were also comparable between the pla-
cebo group and the 4 mg baricitinib group (IR of 0.5 per 
100 patient- years for both) during the 24- week placebo- 
controlled period, as well as between the 2 mg and 4 mg 
baricitinib dose groups in the 2 mg–4 mg-extended data set 
(Figure 2A and Table 3). The IR of ATE in the All- bari- RA data 
set was 0.4 per 100 patient- years, and remained stable over 
time (Figure 2B).
Similarly, rates of reported CHF, based on both broad and 
narrow MedDRA SMQ terms, were not increased during the first 
24 weeks of treatment in patients who received 4 mg baricitinib 
 compared to those who received placebo, and did not differ 
between the two  baricitinib dose groups during extended obser-
vation (Table 3).
Table 2. Characteristics of the study patients and treatment exposure*
Placebo- controlled (to week 24) 2 mg–4 mg-extended




4 mg bari 
(n = 997)
2 mg bari 
(n = 479)
4 mg bari 
(n = 479)
Baseline characteristic
Age, years 52.9 ± 11.9 53.7 ± 12.0 53.2 ± 12.0 53.6 ± 11.7 52.9 ± 12.2
Age ≥65 years, no. (%) 173 (16.2) 199 (20.0) 82 (17.1) 87 (18.2) 612 (17.5)
Female, no. (%) 862 (80.6) 794 (79.6) 386 (80.6) 391 (81.6) 2,760 (79.0)
BMI, kg/m2 27.8 ± 7.1 28.0 ± 6.8 29.0 ± 7.4 29.2 ± 7.6 27.7 ± 6.7
BMI ≥30 kg/m2, no. (%) 333 (31.1) 301 (30.2) 184 (38.4) 174 (36.3) 1,070 (30.6)
Duration of RA, years‡ 8.9 ± 8.4 8.9 ± 8.6 9.0 ± 8.1 9.1 ± 8.6 7.7 ± 8.2
Methotrexate use, no. (%) 967 (90.4) 903 (90.6) 386 (80.6) 394 (82.3) 2,661 (76.2)
SJC of 66 joints 15.0 ± 9.2 14.8 ± 8.0 15.7 ± 10.4 14.5 ± 7.7 12.0 ± 9.6§
TJC of 68 joints 23.8 ± 14.3 24.0 ± 13.8 25.6 ± 15.3 24.7 ± 14.6 19.6 ± 15.2§
CDAI 37.2 ± 12.7 37.7 ± 12.4 38.4 ± 13.3 37.3 ± 12.6 30.8 ± 16.7§
DAS28- CRP 5.6 ± 0.95 5.7 ± 0.94 5.7 ± 0.96 5.6 ± 0.95 5.1 ± 1.47§
DAS28- ESR 6.3 ± 0.99 6.4 ± 0.96 6.4 ± 0.99 6.3 ± 0.98 5.7 ± 1.54§
Corticosteroid use, no. (%)¶ 610 (57.0) 538 (54.0) 246 (51.4) 250 (52.2) 1,754 (50.2)
Tobacco use, no. (%) 198 (19.1) 196 (20.3) 84 (17.6) 87 (18.2) 663 (20.0)
Exposure#
Total patient- years 393.8 409.4 604.9 645.9 7,860.3
Patients with ≥52 weeks of 
 exposure, no. (%)
─ ─ 172 (35.9) 230 (48.0) 2,723 (78.0)
Patients with ≥104 weeks of 
exposure, no. (%)
─ ─ 122 (25.5) 103 (21.5) 2,182 (62.5)
Longest exposure, days 235 211 1,487 2,202 2,230
* Except where indicated otherwise, values are the mean ± SD. bari = baricitinib; BMI = body mass index; SJC = swollen joint count; TJC = ten-
der joint count; CDAI = Clinical Disease Activity Index; DAS28- CRP = Disease Activity Score in 28 joints using C- reactive protein level; DAS28- 
ESR = DAS28 using erythrocyte sedimentation rate. 
† The All- bari- RA data analysis set (patients who received any baricitinib dose) included patients who switched from placebo, adalimumab, or 
methotrexate to baricitinib, in addition to patients who were randomized to receive any baricitinib dose. Thus, the group is larger than the 
2- mg and 4- mg baricitinib groups added together. 
‡ Measured from the date of rheumatoid arthritis (RA) diagnosis. 
§ For these baseline measurements, 3,439 patients were assessed, since data were available from the phase II/III studies only. 
¶ At time of first treatment dose. 
# Not including observation time after permanent study drug discontinuation. 
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Incidence rates of VTE. During the 24- week placebo- 
controlled period, VTEs (events of DVT and/or PE) were 
reported in 6 of 997 patients randomized to and treated with 
4 mg baricitinib and in 0 of 1,070 patients in the placebo 
group (Figure 3A and Table 3). The events were identified in 
2 of the completed phase III studies, RA- BEAM (n = 4) and 
RA- BUILD (n = 2) (2,3); accordingly, from the subset of 4 
studies that included both the 2 mg and 4 mg doses of baric-
itinib (phase II studies NCT01185353 and NCT01469013 and 
phase III studies RA- BUILD and RA- BEACON [3,4,19,20]), 
the number of DVT/PE events reported during the 24- week 
placebo- controlled period in the placebo group, 2 mg baric-
itinib group, and 4 mg baricitinib group was 0, 0, and 2, 
respectively. A PE event (fatal) was also reported in the active 
Table 3. Incidence of MACE, ATE, CHF, and DVT/PE by data analysis set*
Event
Placebo- controlled (to week 24) 2 mg–4 mg-extended




2 mg bari 
(n = 479)†
4 mg bari 
(n = 997)
2 mg bari 
(n = 479)
4 mg bari 
(n = 479)
MACE‡ 2 (0.5)§ 0¶ 3 (0.8)§ 1 (0.2)# 2 (0.4)# 38 (0.5)
MI 1 (0.3)§ 0¶ 1 (0.3)§ 1 (0.2)# 1 (0.2)# 17 (0.2)
CV- related death 1 (0.3)§ 0¶ 2 (0.5)§ 0# 1 (0.2)# 11 (0.2)
Stroke 1 (0.3)§ 0¶ 1 (0.3)§ 0# 1 (0.2)# 15 (0.2)
ATE** 2 (0.5) 2 (1.0) 2 (0.5) 3 (0.5) 3 (0.5) 35 (0.4)
CHF 
TEAEs††
Broad terms 17 (4.3) 7 (3.8) 10 (2.4) 14 (2.3) 19 (2.9) 128 (1.6)
Narrow terms 1 (0.3) – 1 (0.2) 3 (0.5) 1 (0.2) 19 (0.2)
SAEs††
Broad terms 0 0 1 (0.2) 1 (0.2) 2 (0.3) 11 (0.1)
Narrow terms 0 0 1 (0.2) 1 (0.2) 2 (0.3) 10 (0.1)
DVT/PE
TEAEs
DVT/PE 0 0 6 (1.4) 3 (0.5) 4 (0.6) 42 (0.5)
DVT 0 0 3 (0.7) 3 (0.5) 2 (0.3) 30 (0.4)
PE 0 0 3 (0.7) 1 (0.2) 2 (0.3) 19 (0.2)
SAEs
DVT/PE 0 0 3 (0.7) 3 (0.5) 3 (0.5) 28 (0.4)
DVT 0 0 1 (0.2) 3 (0.5) 1 (0.2) 17 (0.2)
PE 0 0 2 (0.5) 1 (0.2) 2 (0.3) 17 (0.2)
* Values for major adverse cardiovascular events (MACE), arterial thrombotic events (ATE), and deep vein thrombosis/pulmonary embolism 
(DVT/PE) treatment- emergent adverse events (TEAEs) and serious adverse events (SAEs) are the number of rheumatoid arthritis (RA) patients 
with the event (incidence rate [IR]), with IRs calculated as the number of unique patients with the event per 100 patient- years of observation 
time. Values for congestive heart failure (CHF) TEAEs and SAEs are the number of RA patients with the event (exposure- adjusted incidence 
rate [EAIR]), with EAIRs calculated as the number of unique patients with the event per 100 patient- years of exposure time. 
† The data for 2 mg baricitinib (bari) in the placebo- controlled data analysis set are derived from 4 studies in which both 2 mg and 4 mg 
baricitinib were options during randomization. 
‡ In the phase III trials and long- term extension (LTE) study, potential MACE (myocardial infarction [MI], stroke, cardiovascular [CV]–related 
death), and other CV events (hospitalization for unstable angina, hospitalization for heart failure, serious arrhythmia, resuscitated sudden 
death, cardiogenic shock, or coronary revascularizations) were adjudicated by an independent, external Clinical Endpoint Committee. 
§ For these measurements, 892 patients in the placebo group and 891 in the 4 mg baricitinib group were assessed, since data were available 
from the phase III studies only. 
¶ For these measurements, 403 patients in the 2 mg baricitinib group were assessed, since data were available from the phase III studies 
only. 
# For these measurements, 403 patients in the 2 mg baricitinib group and 420 patients in the 4 mg baricitinib group were assessed. 
** ATE comprised MI and ischemic stroke, as well as Medical Dictionary for Regulatory Activities (MedDRA) preferred terms indicative of 
other acute ATE; where available (phase III for applicable event types), adjudicated data were used. 
†† Events were identified based on the MedDRA Cardiac Failure SMQ (20000004). Broad terms include all possible events indicative of cardi-
ac failure, according to MedDRA version 18.0 for the placebo- controlled data set and version 20.0 for the 2 mg–4 mg-extended and All- bari- 
RA data sets. Narrow terms are those that are highly likely to represent the condition of interest. 
CV SAFETY IN BARICITINIB- TREATED RA PATIENTS |      7
comparator (MTX monotherapy) group during the phase III 
study RA- BEGIN.
Of the 6 baricitinib- treated patients with reported DVT/
PE during the placebo- controlled period, all had conventional 
risk factors, including severe or morbid obesity (body mass 
index [BMI] between 35 and <40 kg/m2 or ≥40 kg/m2) in 5 
of the 6 patients (see Supplementary Table 1, available on 
the Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.40841/abstract). Four patients 
continued to be treated with baricitinib following the event, 
and remained on treatment for ~2 years prior to the data 
cutoff point, without recurrence of an event (3 also received 
anticoagulation therapy). Of the remaining 2 patients, 1 had 
previously discontinued treatment 1 month prior to the event 
(28 days after the last baricitinib dose) and the other inter-
rupted treatment, resumed, and then discontinued 2 months 
after the event.
According to the program design, patients in the placebo 
group were transitioned to treatment with 4 mg baricitinib fol-
lowing the placebo- controlled period or following rescue during 
that period. Among these 928 patients, 1 event was reported 
during the 24- week period following transition from placebo to 
4 mg baricitinib (Figure 3B). The event (DVT) occurred 2 days 
following a femur fracture. The patient was treated with aspirin, 
Figure 1. Cumulative incidence rates (IRs) of positively adjudicated major adverse cardiovascular events (MACE) (all events occurring on 
study) by data analysis set (A), and IRs of positively adjudicated MACE (all events occurring on study) by time period in rheumatoid arthritis 
patients with all baricitinib exposures at any dose (All- bari- RA data analysis set) (B). Symbols with bars indicate the IRs with 95% confidence 



















































































Baricitinib 4-mg Monotherapy (RA-BEGIN)













































































TAYLOR ET AL 8       |
recovered, and continued to receive baricitinib. In addition, in the 
451 patients who were transitioned from MTX or adalimumab to 
4 mg baricitinib following either rescue or study completion (RA- 
BEGIN and RA- BEAM, respectively), no DVT/PE events were 
reported in the first 24 weeks of baricitinib exposure.
The IR of DVT/PE in the All- bari- RA data set was 0.5 (42 
patients with events through 7,948.6 patient-years of expo-
sure) (Table 3). Of the events reported, evidence of confirma-
tion using imaging was provided for 22 of the 30 patients with 
DVT and 17 of the 19 patients with PE. The IRs of DVT/PE did 
not increase over time (Figure 3C), and were also not clus-
tered early in exposure, accruing at a stable rate of ~0.5% per 
year, with a range from first baricitinib dose to diagnosis of 37 
to 1,658 days (see Supplementary Figure 2, available on the 
Arthritis & Rheumatology web site at http://onlinelibrary.wiley.
com/doi/10.1002/art.40841/abstract). Of the 42 patients 
who reported a DVT/PE among the 3,492 baricitinib- treated 
patients in the All- bari- RA data set, 28 patients were exposed 
to baricitinib after the DVT/PE had occurred (ranging from 7 
days to 30 months after the event; 22 patients received baric-
itinib ≥6 months after the event), either with (n = 25) or without 
(n = 3) continuous anticoagulation. Among these 28 patients, 
2 reported experiencing an additional event 1–2 years after 
the first occurrence and had recent risk factors (prior surgery 
and discontinuation of warfarin) for the reoccurrence.
There was no observed baricitinib dose response during 
extended observation (Table 3 and Figure 3A), and no apparent 
relationship was observed between plasma drug concentra-
Figure 2. Cumulative IRs of adjudicated arterial thrombotic events (ATE) (all events occurring on study) by data analysis set (A), and IRs of ATE 
by time period in the All- bari- RA data analysis set (B). Symbols with bars indicate the IRs with 95% confidence intervals per 100 patient- years 
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tions and occurrence of DVT/PE (see Supplementary Figures 
3A and B, available on the Arthritis & Rheumatology web site at 
http://onlinelibrary.wiley.com/doi/10.1002/art.40841/abstract).
A panel of factors was assessed for association with the 
risk of DVT/PE, using single- variable and multivariable analy-
ses of data from the All- bari- RA data analysis set, comparing 
Figure  3. Cumulative IRs of the venous thromboembolic events of deep vein thrombosis (DVT) and pulmonary embolism (PE) by data 
analysis set (A), IRs of DVT/PE in patients who initially received placebo and were subsequently treated with 4 mg baricitinib following protocol- 
mandated switch or rescue (events during the first 24 weeks after switch), with patients who switched from active comparator (adalimumab 
or methotrexate) to 4 mg baricitinib in the All- bari- RA data analysis set are also noted (B), and IRs of DVT/PE by time period in the All-bari-RA 
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risks between patients with events (n = 42) and those with-
out events (n = 3,450) (see Supplementary Table 2, available 
on the Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.40841/abstract). Factors found to 
be associated with DVT/PE in both single- variable and multi-
variable analyses were a previous history of DVT/PE, increased 
age, increased BMI, and selective cyclooxygenase 2 (COX- 2) 
inhibitor use at baseline (see Supplementary Figure 4, available 
on the Arthritis & Rheumatology web site at http://onlinelibrary.
wiley.com/doi/10.1002/art.40841/abstract); no other variables 
were associated with either a higher risk or lower risk of DVT/
PE in the multivariable model.
It has been shown that baricitinib treatment is associated 
with an increase in the mean platelet count, which peaks at 2 
weeks (mean increase ~50 × 109/liter), then returns to remain 
slightly above baseline thereafter (~20 × 109/liter) (27). Of note, 
no platelet count parameters (absolute and categorized base-
line platelet counts prior to first baricitinib dose, change in plate-
let count from baseline to 2 weeks, and absolute and catego-
rized maximum post–baseline platelet counts) were significantly 
associated with incidence of DVT/PE in either single- variable or 
multivariable analyses. The pattern of platelet counts over time 
was similar in those with and those without reported DVT/PE 
(Supplementary Figures 5A–C, available on the Arthritis & Rheu-
matology web site at http://onlinelibrary.wiley.com/doi/10.1002/
art.40841/abstract).
DISCUSSION
There are several key findings from this study. With 
regard to incidence of MACE, the IRs were similar between 
the placebo and 4 mg baricitinib groups, were comparable 
between baricitinib dose groups, and did not increase with 
prolonged exposure. Furthermore, the findings did not sug-
gest an association between baricitinib treatment and inci-
dence of ATE or CHF. With regard to VTE (DVT and/or PE), 
an imbalance was seen in the 24- week placebo- controlled 
period, with events reported in the 4 mg baricitinib dose 
group but not in the placebo group. The number of events 
underlying this imbalance was small, and was not replicated 
during the first 24 weeks of treatment with 4 mg baricitinib 
among patients who  transitioned to baricitinib from placebo 
or from the active comparator groups. During extended 
observation, the IRs were similar between the baricitinib 
dose groups, were consistent over time, and were compara-
ble to those previously reported in patients with RA (7,8,28–
34). There was no observed association between platelet 
levels and incidence of VTE.
Dose- dependent increases in total high- density lipopro-
tein (HDL) and LDL cholesterol levels have been reported with 
JAK inhibitor treatment, but no association with MACE has 
been observed (26,35). Similar changes in lipid levels have 
been observed with interleukin- 6 (IL- 6) receptor blockade, but 
a recent randomized clinical trial analyzing MACE in patients 
with RA found no significant difference in the rate of MACE 
when comparing tocilizumab with etanercept (36). Larger 
observational studies have yielded similar findings (37,38). The 
lack of evidence to date of an increase in such CV events with 
baricitinib treatment aligns with these observations with regard 
to other therapies that have been linked to increased LDL and 
HDL levels.
Patients with RA may be at increased risk of VTE due 
to immobility, surgery, other comorbidities, and the underlying 
pathobiology of their disease. Observational studies suggest 
that patients with RA are at a 2–3- fold increased risk of VTE 
compared to the general population (15–17). The reported VTE 
incidence among patients with RA ranges from 0.3 to 0.8 per 
100 patient- years (7,8,28–34). The reported incidence rate, 
an absolute measure, is influenced by the definitions used to 
identify the event. For example, Kim et al (8) included only seri-
ous cases of VTE found in hospital discharge diagnosis codes, 
while other studies, such as the study by Yusuf et al (33), have 
identified VTE based on a combination of diagnostic codes 
from hospital and outpatient care settings. Differences in rates 
may also be attributed to differences in the distribution of risk 
factors for VTE across populations; for example, older popu-
lations will have higher incidence rates than younger ones. In 
the baricitinib clinical trial program reported herein, VTE cases 
were identified from both inpatient and outpatient settings, 
and the overall VTE incidence rate (IR of 0.5 per 100 patient- 
years) fell within the range reported in the literature for RA pop-
ulations in North America and Europe (7,8,28–34). Of note, 
the 6 patients with reported DVT/PE who received baricitinib 
during the placebo- controlled period had risk factors for VTE. 
Incidence did not increase over time with continued exposure 
to baricitinib, and rechallenge with baricitinib after an event 
was not associated with acute recurrence.
Single- variable and multivariable risk factor analyses 
were performed using data from baricitinib- treated patients 
with an event (n = 42) and those without an event (n = 
3,450). Factors from both analyses that were found to be 
independently associated with an event were a previous his-
tory of DVT/PE, increased age, and increased BMI. These 
are among the traditional risk factors for DVT/PE that have 
been identified in the general population (39). Use of selec-
tive COX- 2 inhibitor treatment at baseline was also shown to 
be associated with event incidence. An increased risk of VTE 
in patients treated with nonsteroidal antiinflammatory agents, 
including COX- 2 inhibitors, has been reported previously 
(40). Supporting the validity of the findings from the pres-
ent study, the magnitudes of DVT/PE risk increase for BMI 
≥35 kg/m2 and for COX-2 inhibitor use were similar in this 
RA program to previously published risk ratios in the general 
population (40,41).
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However, the question remains as to whether there is a 
mechanistic link between JAK inhibition and the uncommon 
occurrence of VTE in patients with RA, and if so, whether it 
would be a class effect. An analysis of VTE across tofacitinib 
randomized controlled trials did not show evidence of an 
imbalance of events compared to placebo, while recently pre-
sented real- world evidence from the United States showed a 
numerically higher, but statistically nonsignificant, risk of VTE 
with tofacitinib compared to tumor necrosis factor inhibitors in 
RA patients (42,43). In the placebo- controlled periods of the 
phase III SELECT studies, including SELECT- NEXT (period 
of 0–12 weeks), SELECT- BEYOND (period of 0–12 weeks), 
SELECT- COMPARE (period of 0–26 weeks), and SELECT- 
MONOTHERAPY (period of 0–24 weeks), VTE was reported to 
be present in 1 patient in the placebo group and 4 patients in 
the 15 mg upadacitinib group (44–47). A dose response was 
not seen (44,45,47,48). Of interest, in the controlled period of 
SELECT- COMPARE, unlike the similarly designed RA- BEAM 
study, where 4 of the 6 VTEs reported for baricitinib compared 
to placebo arose, events were reported not only in the JAK 
inhibitor group (n = 2), but also in the placebo group (n = 1) and 
the active comparator adalimumab group (n = 3). Additional 
VTE events have been reported to occur with  upadacitinib after 
controlled study periods, and an IR of 0.7 per 100 patient- years 
has been described from phase II studies and their long- term 
extensions (49).
VTE is a recognized risk factor in patients with RA. Imbal-
ances in the incidence of VTE between those receiving active 
DMARDs and those receiving placebo in a controlled clinical 
setting may suggest an association with VTE risk; however, the 
totality of available evidence must be weighed. With respect to 
reversible JAK inhibition and an increased risk of VTE, a bio-
logic mechanism remains unclear, and a causal relationship has 
yet to be established. From a clinical management perspective, 
as when recommending any pharmacotherapy, the potential 
benefits and risks should be taken into account. Moreover, cli-
nicians need to bear in mind that RA is, in itself, a risk factor 
for VTE and should consider whether other risk factors are also 
present.
This study has a number of limitations. The potential events of 
DVT/PE were not subject to adjudication by a committee external 
to the sponsor. Although most events (73% of DVTs, 90% of PEs) 
were reported to have been verified using imaging, this was not 
the case for all events. Thus, while the present approach to case 
acquisition is likely to have been adequately sensitive, adjudication 
may have increased specificity. In addition, the restricted placebo- 
controlled period and the overall size of this (and other) devel-
opment programs are inherently limited in their ability to reliably 
detect or rule out associations between a drug and uncommon or 
rare AEs. Accordingly, it is important that such potential risks be 
carefully characterized on an ongoing basis via pharmacovigilance 
activities, including studies in larger, longer- term cohorts during 
real- world use.
In addition, contextual data on the incidence of DVT/PE 
are limited, since the overall IRs of DVT/PE, including nonseri-
ous as well as serious events, have not been routinely reported 
from prior RA development programs. The closest comparative 
data  available to the authors were the rates of serious DVT 
and serious PE reported from the development program for 
sarilumab, a recently- approved biologic DMARD targeting the 
IL- 6 pathway. These studies were conducted at approximately 
the same time as the present program, and available data 
showed that the IRs of serious DVT as well as serious PE were 
~0.2 per 100 patient- years for each event type separately in 
the sarilumab plus DMARD population (5,845 patient- years of 
exposure) and in the all- bari- RA data set (50). Given the limited 
clinical trial data available, rates of DVT/PE from observational 
studies were used to put the rates seen in the baricitinib devel-
opment program into context. It is acknowledged that real- 
world data sources likely differ from clinical trial populations, 
both in terms of baseline risk and ascertainment of events, 
and are thus not directly comparable. However, risk factors for 
DVT/PE were not used as exclusion criteria in the baricitinib 
studies, and comorbidities, including known VTE risks such as 
elevated BMI, were well- represented in the enrolled sample. 
The observational data do illustrate that the background rate 
of VTE in RA is not zero, in contrast to that seen in the placebo 
group of the present program.
In summary, the findings from this large integrated data 
set indicate that there is no association between exposure to 
baricitinib and incidence of MACE, ATE, or CHF in patients with 
RA. Despite an imbalance in the occurrence of VTE between 
the baricitinib- and placebo- treated patients in the placebo- 
controlled study periods, the overall IRs of VTE in baricitinib- 
treated patients fell within the reported range for patients with 
RA. Given the limited number of reported events in this inte-
grated data set from phase II and phase III trials, rates of these 
and other CV events will continue to be characterized during 
treatment with baricitinib, including during real- world use in 
countries where it is approved.
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